Hims & Hers Health (NYSE:HIMS) Initiates Stock Buyback Program

Hims & Hers Health (NYSE:HIMS) announced that its board has approved a stock repurchase program on Monday, November 17th, RTT News reports. The company plans to buyback $250.00 million in outstanding shares. This buyback authorization allows the company to buy up to 3% of its shares through open market purchases. Shares buyback programs are usually a sign that the company’s board of directors believes its stock is undervalued.

Analysts Set New Price Targets

Several equities analysts have issued reports on HIMS shares. Wall Street Zen cut shares of Hims & Hers Health from a “hold” rating to a “sell” rating in a research note on Saturday, November 8th. Weiss Ratings restated a “hold (c)” rating on shares of Hims & Hers Health in a research report on Tuesday, November 11th. BTIG Research restated a “buy” rating and issued a $85.00 target price on shares of Hims & Hers Health in a report on Tuesday, November 4th. Bank of America boosted their target price on shares of Hims & Hers Health from $28.00 to $32.00 and gave the company an “underperform” rating in a research note on Tuesday, November 4th. Finally, UBS Group set a $32.00 price target on Hims & Hers Health in a research note on Tuesday, November 4th. Two research analysts have rated the stock with a Buy rating, ten have given a Hold rating and three have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Reduce” and an average price target of $45.27.

Hims & Hers Health Trading Down 3.7%

Hims & Hers Health stock opened at $35.63 on Tuesday. The stock has a 50-day moving average price of $50.35 and a 200 day moving average price of $51.45. The company has a market capitalization of $8.11 billion, a price-to-earnings ratio of 65.98, a price-to-earnings-growth ratio of 7.36 and a beta of 2.20. Hims & Hers Health has a 52 week low of $19.29 and a 52 week high of $72.98. The company has a quick ratio of 1.64, a current ratio of 1.88 and a debt-to-equity ratio of 1.67.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings results on Monday, November 3rd. The company reported $0.06 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.03). Hims & Hers Health had a return on equity of 24.67% and a net margin of 6.05%.The business had revenue of $598.98 million for the quarter, compared to analysts’ expectations of $578.99 million. During the same period in the prior year, the business posted $0.32 earnings per share. The business’s quarterly revenue was up 49.2% compared to the same quarter last year. Hims & Hers Health has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. Sell-side analysts anticipate that Hims & Hers Health will post 0.29 EPS for the current year.

Insider Buying and Selling

In other Hims & Hers Health news, insider Michael Chi sold 13,749 shares of the stock in a transaction dated Wednesday, September 17th. The stock was sold at an average price of $50.50, for a total transaction of $694,324.50. Following the sale, the insider directly owned 297,139 shares of the company’s stock, valued at approximately $15,005,519.50. This trade represents a 4.42% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Andrew Dudum sold 128,127 shares of Hims & Hers Health stock in a transaction dated Tuesday, September 16th. The shares were sold at an average price of $53.48, for a total value of $6,852,231.96. Following the transaction, the chief executive officer owned 160,425 shares of the company’s stock, valued at $8,579,529. The trade was a 44.40% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 584,209 shares of company stock valued at $31,837,916 over the last 90 days. Insiders own 17.71% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.